The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jon Young - Canaccord Genuity (Australia) Ltd - Analyst
: Great, thanks and thanks again for that great overview of the company. And I think it would be great, actually start off on guidance, on everyone's
favorite question. But as you just talked value provided 24 guidance on the earnings call, which was revenue of $328 million to $333 million, which
Question: Jon Young - Canaccord Genuity (Australia) Ltd - Analyst
: Okay, great. And then moving to the Med Device business. CEO, can you speak about what you're seeing today in the field from that. In particular,
what are your thoughts on the current backlog? I know it was standing at $2.7 million end of Q4 and just the impact of that backlog going forward
tail? And just how that impacts growth?
Question: Jon Young - Canaccord Genuity (Australia) Ltd - Analyst
: And then I think it was moved to another important topic question, that was the recent divestiture. If you know, it happened early in the fiscal year.
You divested both the Dialysis and the BioSentry product line to Merit Medical for $100 million in cash. The sale helped you pay off your debt.
And from the balance sheet footing, can you just talk about operating leverage. First, how should investors think of the direct versus indirect costs
to the sold businesses, timing of when you might right-size the costs in each of those businesses, if at all? And then also what key variables to be
making those decisions in terms of the future divestments or more.
Question: Jon Young - Canaccord Genuity (Australia) Ltd - Analyst
: And just to follow up on that, too. Can you talk about your thoughts on striking the balance between leveraging the cash flow provided by the
remaining business, versus the potential future divestitures, and thoughts surrounding?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 09, 2023 / 12:00PM, ANGO.OQ - AngioDynamics Inc at Canaccord Genuity Growth Conference
Question: Jon Young - Canaccord Genuity (Australia) Ltd - Analyst
: Got it. And then I know you've guided here our cash flow breakeven by the end of fiscal year 2025. Does that guidance contemplate the Med
Devices business remain the same size as it is today?
Question: Jon Young - Canaccord Genuity (Australia) Ltd - Analyst
: Okay, great. And then let's move to the MedTech business, which is really exciting because they have off high growth and becoming much more
important part of the business. Based on Auryon for atherectomy, which in our view, has been the best performance to date.
First, can you talk about the capital environment you see today, especially as we begin to focus on hospital outpatient sales, versus the office-based
labs? How penetrated are you today in US OBLs, and hospital outpatient adjustment?
Question: Jon Young - Canaccord Genuity (Australia) Ltd - Analyst
: Got it. And then you spoke about -- international expansion. Are you charging a CE mark in the first half of fiscal 2024. How should we think about
this the OUS opportunity when it comes to Auryon, but also in terms of distribution strategy and commercial ramp, would you sell through
distributors? And then what reimbursement exists, OUS today in terms like countries you would initially target?
Question: Jon Young - Canaccord Genuity (Australia) Ltd - Analyst
: Great, we have a few seconds left. We'll sneak one more in here, but just the regulatory process related to the expansion into coronary. I think
investors are probably very interesting that, given all the high growth in coronary, would you expect the best use case to be there? And how do
you think you can compete against the existing technology is already on the market there today.
| 
